Abstract: An antibody has an antagonistic effect against IL-33. An isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

Abstract: An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

Abstract: An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

Abstract: The polynucleotide construct of (1) or (2) below is used to perform ribosome display, CIS display and/or mRNA display in order to screen a Fab against an antigen of interest: (1) a polynucleotide construct which monocistronically comprises a ribosome-binding sequence, Fab first chain-coding sequence, linker peptide-coding sequence, Fab second chain-coding sequence and scaffold-coding sequence in this order, and further comprises at its 3?-end a structure necessary for maintaining a complex with the Fab encoded by itself; and (2) a polynucleotide construct which comprises a Fab first chain-expressing cistron and a Fab second chain-expressing cistron each containing a ribosome-binding sequence, a Fab first chain-coding sequence or Fab second chain-coding sequence, and a scaffold-coding sequence in this order, the first Fab-expressing cistron further comprising at its 3?-end a ribosome stall sequence, said Fab second chain-expressing cistron further comprising at its 3?-end a structure necessary for maintaining

Abstract: An antibody has an antagonistic effect against IL-33. In particular an isolated human anti-IL-33 neutralizing monoclonal antibody has framework regions with amino acid sequences from a germline, including combinations and fragments of such sequences. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce the foregoing human anti-IL-33 neutralizing monoclonal antibodies having framework regions.

Abstract: An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.

Abstract: The polynucleotide construct of (1) or (2) below is used to perform ribosome display, CIS display and/or mRNA display in order to screen a Fab against an antigen of interest: (1) a polynucleotide construct which monocistronically comprises a ribosome-binding sequence, Fab first chain-coding sequence, linker peptide-coding sequence, Fab second chain-coding sequence and scaffold-coding sequence in this order, and further comprises at its 3?-end a structure necessary for maintaining a complex with the Fab encoded by itself; and (2) a polynucleotide construct which comprises a Fab first chain-expressing cistron and a Fab second chain-expressing cistron each containing a ribosome-binding sequence, a Fab first chain-coding sequence or Fab second chain-coding sequence, and a scaffold-coding sequence in this order, the first Fab-expressing cistron further comprising at its 3?-end a ribosome stall sequence, said Fab second chain-expressing cistron further comprising at its 3?-end a structure necessary for maintaining

Abstract: An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.

Abstract: An object of the present invention is to provide an antibody having antagonistic effect against IL-33, in particular an isolated human anti-IL-33 neutralizing monoclonal antibody wherein amino acid sequences of framework regions are amino acid sequences that are amino acid sequences from a germline or a combination of amino acid sequences thereof, or a fragment thereof. The epitopes for a plurality of anti-IL-33 monoclonal antibodies were identified, human anti-IL-33 neutralizing monoclonal antibodies were obtained, and the complementarity-determining regions that achieve high binding ability to IL-33 was specified by introducing mutations in the complementarity-determining regions. The identified complementarity-determining regions were used to produce a human anti-IL-33 neutralizing monoclonal antibody having framework regions comprising amino acid sequences that are amino acid sequences of a germline or a combination of amino acid sequences thereof.

Abstract: The polynucleotide construct of (1) or (2) below is used to perform ribosome display, CIS display and/or mRNA display in order to screen a Fab against an antigen of interest: (1) a polynucleotide construct which monocistronically comprises a ribosome-binding sequence, Fab first chain-coding sequence, linker peptide-coding sequence, Fab second chain-coding sequence and scaffold-coding sequence in this order, and further comprises at its 3?-end a structure necessary for maintaining a complex with the Fab encoded by itself, and (2) a polynucleotide construct which comprises a Fab first chain-expressing cistron and a Fab second chain-expressing cistron each containing a ribosome-binding sequence, a Fab first chain-coding sequence or Fab second chain-coding sequence, and a scaffold-coding sequence in this order, the first Fab-expressing cistron further comprising at its 3?-end a ribosome stall sequence, said Fab second chain-expressing cistron further comprising at its 3?-end a structure necessary for maintaining

Abstract: A therapeutic drug for cancer containing a substance selected from the group consisting of a novel cyanopyridine derivative, a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate as an active ingredient can be provided.

Abstract: A therapeutic drug for cancer containing a substance selected from the group consisting of a novel cyanopyridine derivative, a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate as an active ingredient can be provided.

Abstract: Provided is a disconnection and short detecting circuit capable of detecting disconnection and short of a signal line transmitting a differential clock signal. A differential buffer part DB1 has a first comparator to compare a non-inverting clock signal inputted from a PADI and an inverting clock signal inputted from a PADR; a second comparator to compare a non-inverting clock signal and a reference potential Vref; and a third comparator to compare an inverting clock signal and the reference potential Vref. Their respective outputs are defined as Y, YI and YR, respectively. If the signal line of either a non-inverting clock signal or an inverting clock signal is disconnected, or short-circuited to a grounding potential VSS of a logical value Low, the logical values outputted from the second and the third comparators are equal for a long period of time in one cycle of the non-inverting clock signal or the inverting clock signal.

Abstract: Provided is a disconnection and short detecting circuit capable of detecting disconnection and short of a signal line transmitting a differential clock signal. A differential buffer part DB1 has a first comparator to compare a non-inverting clock signal inputted from a PADI and an inverting clock signal inputted from a PADR; a second comparator to compare a non-inverting clock signal and a reference potential Vref; and a third comparator to compare an inverting clock signal and the reference potential Vref. Their respective outputs are defined as Y, YI and YR, respectively. If the signal line of either a non-inverting clock signal or an inverting clock signal is disconnected, or short-circuited to a grounding potential VSS of a logical value Low, the logical values outputted from the second and the third comparators are equal for a long period of time in one cycle of the non-inverting clock signal or the inverting clock signal.

Abstract: Provided is a disconnection and short detecting circuit capable of detecting disconnection and short of a signal line transmitting a differential clock signal. A differential buffer part DB1 has a first comparator to compare a non-inverting clock signal inputted from a PADI and an inverting clock signal inputted from a PADR; a second comparator to compare a non-inverting clock signal and a reference potential Vref; and a third comparator to compare an inverting clock signal and the reference potential Vref. Their respective outputs are defined as Y, YI and YR, respectively. If the signal line of either a non-inverting clock signal or an inverting clock signal is disconnected, or short-circuited to a grounding potential VSS of a logical value Low, the logical values outputted from the second and the third comparators are equal for a long period of time in one cycle of the non-inverting clock signal or the inverting clock signal.

Abstract: Provided is a disconnection and short detecting circuit capable of detecting disconnection and short of a signal line transmitting a differential clock signal. A differential buffer part DB1 has a first comparator to compare a non-inverting clock signal inputted from a PADI and an inverting clock signal inputted from a PADR; a second comparator to compare a non-inverting clock signal and a reference potential Vref; and a third comparator to compare an inverting clock signal and the reference potential Vref. Their respective outputs are defined as Y, YI and YR, respectively. If the signal line of either a non-inverting clock signal or an inverting clock signal is disconnected, or short-circuited to a grounding potential VSS of a logical value Low, the logical values outputted from the second and the third comparators are equal for a long period of time in one cycle of the non-inverting clock signal or the inverting clock signal.

Abstract: The present invention provides an interconnection area decision processor for deciding vertical widths of areas employed for interconnection of a gate array. The interconnection area decision processor predicts which interconnection area each signal net passes on the basis of previously created data on cell arrangement and data on arrangement of transistor rows on a chip to estimate interconnection congestion per channel on the basis of the result of prediction and decide the number of transistor rows to be assigned to each channel on the basis of the estimated interconnection congestion, thereby to create data on the vertical width of each channel. Thus, density of integration can be improved by increasing the number of tracks of channels having large numbers of interconnections and decreasing the number of tracks of channels having small numbers of interconnections.